Background: There is no suggested molecular indicator for the determination of which
patients will benefit from anti-angiogenetic treatment in metastatic colorectal cancers …

Background: No factor has thus far been identified to predict the efficacy of bevacizumab
therapy for colorectal cancer. We here therefore studied PTEN, VEGF, HER2 and p53 by …

Objective: To evaluate the efficacy and safety of bevacizumab in the treatment of patients
with metastatic colorectal cancer (mCRC). Methods: In a single-center, observational study …

Objective: Angiogenesis represents a key element in the pathogenesis of malignancy. There
are no robust data on prognostic factors for overall survival (OS) in patients with metastatic …

Background: The purpose of this study was to analyze the predictive value of
neutrophil/lymphocyte ratio (NLR) to better clarify which patient groups will benefit the most …

Background: Efficacy of chemotherapy plus bevacizumab has been shown in patients with
metastatic colorectal cancer (mCRC) compared with chemotherapy alone. The aim of the …

Background: Colorectal carcinoma (CRC) is one of the major causes of cancer death
worldwide. Data from the literature indicate differences between the proliferation rate of …

Introduction We aimed to assess the effect of VEGF-A, PDGF-BB, and c-Met expression
levels on survival in patients with metastatic colorectal cancer receiving bevacizumab …

Purpose: To observe the efficacy and side effects of combined treatment of bevacizumab
and 5-fluorouracil in patients with metastatic colon cancer. Methods: Sixty patients with …

Background Molecular predictors of bevacizumab efficacy in colorectal cancer have not
been identified yet. Specific VEGF polymorphisms may affect gene transcription and …